Connect for Cancer Prevention Study

The Connect for Cancer Prevention Study is an observational study looking at how our lifestyles, genes, and health history might affect cancer risk. Researchers hope to better understand what causes cancer and find new ways to prevent it. This study doesn't test a specific drug or intervention. Instead, it collects information and biological samples over time to see how different factors relate to cancer. The study aims to enroll 200,000 adults, aged 30 to 70, who receive healthcare from one of the partner health systems and have never had cancer. Success for this study means understanding cancer incidence (how often new cancers occur), progression (how cancers change over time), and mortality (death from cancer) starting from year one and continuing.

Study design
This is an observational study planning to enroll 200,000 participants. It will follow participants over time without assigning specific treatments.
What's involved
Participants will be asked to provide repeated information about their exposures and biological specimens. The study will follow participants for cancer and other health outcomes.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for cancer incidence, progression, and mortality starting at year one and onward.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04609072

Connect for Cancer Prevention Study (Connect)

Recruiting
Not specifiedAges 30–70Observational
National Cancer Institute (NCI)
~200,000 participants
Updated 2026-08-28 on ClinicalTrials.gov

At a glance

Recruiting sites
9 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
cancer incidence, progression, and mortality
Measured over year one and onward
Cancer
General Research Use
10 sites across 10 states
Colorado1
Georgia1
Hawaii1
Illinois1
Michigan1
Minnesota1
Oregon1
South Dakota1
  • Nicolas A Wentzensen, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients or members of participating IHCS at the time of enrollment
Age between 30 and 70 years old at study invitation

Exclusion

Individuals with a confirmed history of invasive cancer (other than non-melanoma skin cancer)
Individuals with known cognitive impairment documented in their medical record
  • cancer incidence, progression, and mortalityyear one and onward

    cancer incidence, progression, and mortality outcomes could include, but are not limited to:early biological effects (e.g., inflammation or metabolomic markers) related to cancer, intermediate biomarkers, cancer precursors, cancer risk factors, cancer incidence, cause of death, cancer survival, risk of second cancers and survivorship